Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000802906 | SCV000942755 | pathogenic | Multiple endocrine neoplasia, type 1 | 2022-09-20 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 648226). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MEN1 protein function. This variant disrupts the p.Gly42 amino acid residue in MEN1. Other variant(s) that disrupt this residue have been observed in individuals with MEN1-related conditions (PMID: 9463336, 28203045, 29066490), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. This missense change has been observed in individual(s) with MEN1-related conditions (PMID: 11303512; Invitae). In at least one individual the variant was observed to be de novo. This sequence change replaces glycine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 42 of the MEN1 protein (p.Gly42Ala). This variant is not present in population databases (gnomAD no frequency). |